Operant self‐administration of pregabalin in a mouse model of neuropathic pain

Operant self‐administration of pregabalin in a mouse model of neuropathic pain IntroductionPregabalin is an antiepileptic drug prescribed as first‐line treatment for chronic neuropathic pain (Finnerup et al., ) mainly acting on the α2δ‐1 calcium channel subunit, which is critical for functional expression of voltage‐gated calcium channels (Field et al., ; Patel and Dickenson, ). Multiple preclinical studies have shown the efficacy of pregabalin alleviating hypernociception associated with neuropathic injuries (Field et al., , ; Nozaki‐Taguchi et al., ; Kremer et al., ). While some of these studies describe complete reversion of neuropathic hypersensitivity, it should be noted that the number of patients needed to treat for 50% pain relief (i.e. patients who need to be treated to obtain one with a 50% of pain relief) is estimated between 6.5 and 9.4 (Finnerup et al., ). This discordance between clinical data and preclinical studies may be related to the measurement of evoked sensitivity in the current preclinical studies. While one of the most prevalent symptoms in chronic neuropathic syndromes is spontaneous pain (96% of the cases (Backonja and Stacey, )), studies estimating the efficacy of pregabalin alleviating spontaneous manifestations of neuropathic pain models in mice are lacking.Different clinical studies (Papazisis and Tzachanis, ; Bossard et al., ; Schjerning et al., ; Evoy et al., ) and individual reports (Filipetto et al., http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Pain Wiley

Operant self‐administration of pregabalin in a mouse model of neuropathic pain

Loading next page...
 
/lp/wiley/operant-self-administration-of-pregabalin-in-a-mouse-model-of-0PvcmwvIRh
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Pain Federation ‐ EFIC®
ISSN
1090-3801
eISSN
1532-2149
D.O.I.
10.1002/ejp.1161
Publisher site
See Article on Publisher Site

Abstract

IntroductionPregabalin is an antiepileptic drug prescribed as first‐line treatment for chronic neuropathic pain (Finnerup et al., ) mainly acting on the α2δ‐1 calcium channel subunit, which is critical for functional expression of voltage‐gated calcium channels (Field et al., ; Patel and Dickenson, ). Multiple preclinical studies have shown the efficacy of pregabalin alleviating hypernociception associated with neuropathic injuries (Field et al., , ; Nozaki‐Taguchi et al., ; Kremer et al., ). While some of these studies describe complete reversion of neuropathic hypersensitivity, it should be noted that the number of patients needed to treat for 50% pain relief (i.e. patients who need to be treated to obtain one with a 50% of pain relief) is estimated between 6.5 and 9.4 (Finnerup et al., ). This discordance between clinical data and preclinical studies may be related to the measurement of evoked sensitivity in the current preclinical studies. While one of the most prevalent symptoms in chronic neuropathic syndromes is spontaneous pain (96% of the cases (Backonja and Stacey, )), studies estimating the efficacy of pregabalin alleviating spontaneous manifestations of neuropathic pain models in mice are lacking.Different clinical studies (Papazisis and Tzachanis, ; Bossard et al., ; Schjerning et al., ; Evoy et al., ) and individual reports (Filipetto et al.,

Journal

European Journal of PainWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial